Search By:
Products
Injury
Topic
Company
Industry
Organon's vaginal contraceptive Nuvaring may be defective, causing a greater risk of blood clotting which can lead to heart attack, stroke or death.
Investigation Source
- Nationwide
Investigation Scope
Category Information
Investigation Topic
- Defective Product or Service
Product or Service
- Nuvaring
Injury Types
- Blood Disorders and Clots
- Heart Attack
- Stroke
Investigation Details
Investigation and pending multiple lawsuits against Organon in connection with its manufature of NuvaRing, which is a vaginal contraceptive ring.
NuvaRing contains estrogen and progestin hormones. However, the type of progestin used in the NuvaRing (etonogestrel), is considered a third-generation progestin and is associated with a greater risk for developing blood clots than the type of progestin that is used in most birth control pills. Since the NuvaRing became available in 2002, the U.S. Food and Drug Administration (FDA) has received many reports of adverse events associated with the use of the NuvaRing. The most dangerous side effect is blood clotting, which can lead to a heart attack, stroke, or even death. In 2005, the FDA required Organon to change the NuvaRing label to more accurately reflect the risks associated with it.
Do not change medications without first consulting your doctor.
NuvaRing contains estrogen and progestin hormones. However, the type of progestin used in the NuvaRing (etonogestrel), is considered a third-generation progestin and is associated with a greater risk for developing blood clots than the type of progestin that is used in most birth control pills. Since the NuvaRing became available in 2002, the U.S. Food and Drug Administration (FDA) has received many reports of adverse events associated with the use of the NuvaRing. The most dangerous side effect is blood clotting, which can lead to a heart attack, stroke, or even death. In 2005, the FDA required Organon to change the NuvaRing label to more accurately reflect the risks associated with it.
Do not change medications without first consulting your doctor.
Defendant Details
| Name (Stock Symbol) | Brief Description |
|---|---|
| Organon BioSciences | Organon BioSciences merged with Schering-Plough Corporation d is now part of that pharmaceutical company. |